CHICAGO COMPANIES - Novartis gets approval to market 4 drugs in Japan - MSN MoneyCentral CHICAGO COMPANIES - Novartis gets approval to market 4 drugs in Japan - MSN MoneyCentral

Wednesday, January 21, 2009

CHICAGO COMPANIES - Novartis gets approval to market 4 drugs in Japan - MSN MoneyCentral

BASEL, Switzerland (AP) - Novartis AG said Wednesday it has received approval in Japan to market four drugs to treat asthma, cancer, hypertension and blindness. The Swiss pharmaceuticals company said the approvals covered omalizumab, known as Xolair in Stock and Shares News

The corporate bond market for retail investors is expected to see some hectic activity after many years, with a host of companies such as Tata Capital and the state-owned Indian Infrastructure Finance Company Ltd (IIFCL) planning to float such issues in Stock and Shares News

Set against the gloomy backdrop of a worldwide economic slump, a banking system in meltdown and talk that sterling may eventually reach parity with the dollar, investors are in no mood to stick their heads above the parapet. "It has been a dreadful in Stock and Shares News

By Natsuko Waki LONDON, Jan 21 (Reuters) - Sterling hit fresh 7-1/2 year lows against the dollar and European shares tumbled again on Wednesday as fears intensified about the banking sector, knocking Barclays shares down more than 20 percent in Stock and Shares News

BASEL, Switzerland -- Novartis ( NVS Quote - Cramer on NVS - Stock Picks ) said Wednesday it has received approval in Japan to market four drugs to treat asthma, cancer, hypertension and blindness. More on NVS BioTalk: Novartis' MS Play Novartis MS in Stock and Shares News

Once again, those four lads from Liverpool were right: Money can't buy me love. Just ask Manchester City. Its world-record 100 million pound ($147 million; €111 million) bid for Kaka couldn't make the Brazilian midfielder part with his conscience in Stock and Shares News

No comments: